Key facts
- This page summarizes Robert Chess's Form 5 filing for NEKTAR THERAPEUTICS (NKTR).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 17 Jan 2025, 20:35.
Robert Chess - 31 Dec 2024 Form 5 Insider Report for NEKTAR THERAPEUTICS (NKTR)
- Reporting relationship
- Director
- Issuer ticker
- NKTR
- Reported as of
- 31 Dec 2024
- Net transaction value
- $0
- SEC form
- 5
- Accepted by SEC
- 17 Jan 2025, 20:35:06 UTC
- Prior SEC filing
- 30 Dec 2024
- Next SEC filing
- 10 Jan 2025
- Source filing
- View source filing
- Reporting owner signature
- Mark A. Wilson, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Robert Chess filed Form 5 for NEKTAR THERAPEUTICS (NKTR) on 17 Jan 2025.
Change
- Previous filing in this sequence was filed on 30 Dec 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 5 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
NKTR
transaction
Derivative
Stock Option
Award
- Transaction value
- $0
- Shares
- +120,000
- Change %
- Price
- $0.000000
- Shares after
- 120,000
- Date
- 18 Sep 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 120,000
- Exercise price
- $1.26
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
This stock option vests in equal monthly installments over the one-year period beginning on September 18, 2024.